This therapeutic concept proposes glucocerebrosidase (GCase) enzyme enhancement for individuals carrying GBA mutations who remain pre-symptomatic for Parkinson's disease. By restoring lysosomal glucocerebrosidase activity before alpha-synuclein pathology becomes established, this approach aims to prevent or delay the onset of clinical PD symptoms in this high-risk population.
- GBA mutations are the strongest PD risk factor: Heterozygous GBA mutations increase PD risk 5-20x, with some variants (N370S, L444P) showing particularly high risk
- GCase activity is reduced in GBA carriers: Even heterozygous carriers show ~50% reduction in enzymatic activity, leading to glucosylceramide accumulation
- Glucosylceramide promotes alpha-synuclein aggregation: In vitro and animal studies show that elevated glucosylceramide accelerates alpha-synuclein fibrilization
- Enzyme enhancement is feasible: Small-molecule chaperones (ambroxol, afegostat) can increase GCase activity and reach the CNS
flowchart TD
subgraph Risk_Identification
A["Genetic Testing<br/>GBA sequencing"] --> B["Biomarker Screening<br/>Glucosylceramide, alpha-syn seeds"]
B --> C["GBA Carrier Status"]
end
subgraph I["ntervention"]
C --> D["Pharmacologic Chaperone<br/>Ambroxol 1.2g/day"]
C --> E["Substrate Reduction Therapy<br/>Eliglustat"]
C --> F["Gene Therapy<br/>AAV-GBA"]
end
subgraph M["echanisms"]
D --> G["Restore GCase Activity"]
E --> H["Reduce Glucosylceramide"]
F --> I["Increase Lysosomal GCase"]
end
subgraph O["utcome"]
G --> J["Reduced alpha-synuclein Aggregation"]
H --> J
I --> J
J --> K["Prevention of Dopaminergic Neuron Loss"]
end
| Risk Category |
Genetic Profile |
Age Range |
Biomarker Criteria |
| High Risk |
GBA N370S/L444P homozygous |
35-50 |
Normal DaTscan, elevated GlcCer |
| Moderate Risk |
GBA heterozygous |
40-55 |
Normal cognition, subtle smell loss |
| Prodromal |
GBA+ with RBD |
45-60 |
Positive alpha-syn seeds |
- Ambroxol: FDA-approved expectorant shown to be a GCase chaperone; doses of 1.2g/day have been used in PD clinical trials
- Afegostat (AT222): GCase-specific chaperone that stabilizes and increases enzyme activity
- Eliglustat: Substrate reduction therapy that reduces glucosylceramide production
- AAV-GBA: Deliver functional GBA gene to neurons and astrocytes using AAV vectors
- CRISPR base editing: Edit GBA mutations in situ to restore normal function
- Blood: Glucosylceramide levels, GCase activity
- CSF: Alpha-synuclein seeds (RT-QuIC), total alpha-synuclein
- Imaging: DaTscan at baseline and annually
- Clinical: MDS-UPDRS, smell identification test
| Phase |
Design |
Population |
Primary Endpoint |
| II |
Randomized, placebo-controlled |
GBA carriers, age 40-60 |
Change in CSF alpha-syn seeds at 24 months |
| III |
Open-label extension |
GBA carriers with prodromal PD |
Time to PD diagnosis |
- GBA/Lysosomal Pathway in Parkinson's Disease — Primary mechanism this therapy targets
- Alpha-Synuclein Aggregation Pathway — Pathological process being prevented
- Autophagy-Lysosomal Pathway — Enhanced by GCase restoration
- Lysosomal Dysfunction in Neurodegeneration — Background mechanism
- GBA Gene — Target gene for this therapy
- Alpha-Synuclein — Pathological protein being cleared
- Parkinson's Disease — Target disease
- GBA-associated Parkinson's Disease — Specific subtype
- VPS35 Retromer Stabilizer — Complementary lysosomal target
- USP13 Inhibitor for Mitophagy — Also targets lysosomal function